Select a Region

North America

Newscenter

Browsing Archive: ATTR cardiomyopathyATTR cardiomyopathy | EVERSANA

EVERSANA

Posted on February 1, 20232/1/23

Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies

EVERSANA

Posted on February 1, 20232/1/23

Annual Cardiovascular-related Hospitalization Days Avoided With Tafamidis Treatment in Patients With Transthyretin Amyloid Cardiomyopathy

EVERSANA

Posted on February 1, 20232/1/23

Modelling Lifetime Survival Gain in Patients With Transthyretin Amyloid Cardiomyopathy and Baseline NYHA Class III: An Analysis of ATTR-ACT and Long-Term Extension Study

ATTR cardiomyopathy